A. Van Hecken et al., Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers, J CLIN PHAR, 39(5), 1999, pp. 495-500
Montelukast, a cysteinyl leukotriene receptor antagonist, is being develope
d for the treatment of asthma and related diseases. This study was designed
to evaluate whether montelukast at clinically used dosage levels would int
erfere with the anticoagulant effect of warfarin. In a two-period, double-b
lind, randomized crossover study 12 healthy male subjects received a single
oral dose of 30 mg warfarin on the 7th day of a la-day treatment with mont
elukast, 10 mg daily by mouth, or a placebo. Montelukast had no significant
effect on the area under the plasma concentration-time curves and peak pla
sma concentrations of either R- or S-warfarin. However, slight but statisti
cally significant decreases in time to peak concentration of both warfarin
enantiomers and in elimination half-life of the less potent R-warfarin were
observed in the presence of montelukast. These changes were not considered
as clinically relevant. Montelukast had no significant effect on the antic
oagulant effect of warfarin, as assessed by the international normalized ra
tio (INR) for prothrombin time (AUC(0-144) and INR maximum). The results of
this study suggest that a clinically important interaction between these d
rugs is unlikely to occur in patients requiring concomitant administration
of both drugs. (C) 1999 the American College of Clinical Pharmacology.